G

GI Innovation Inc
KOSDAQ:358570

Watchlist Manager
GI Innovation Inc
KOSDAQ:358570
Watchlist
Price: 10 030 KRW -4.11% Market Closed
Market Cap: 443.5B KRW
Have any thoughts about
GI Innovation Inc?
Write Note

Net Margin
GI Innovation Inc

-983.3%
Current
-3 546%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-983.3%
=
Net Income
-46.8B
/
Revenue
4.8B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
KR
GI Innovation Inc
KOSDAQ:358570
443.3B KRW
-983%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
312.7B USD
9%
US
Amgen Inc
NASDAQ:AMGN
158.3B USD
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD
-5%
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD
0%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
133.6B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.5B EUR
-14%
Country KR
Market Cap 443.3B KRW
Net Margin
-983%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 312.7B USD
Net Margin
9%
Country US
Market Cap 158.3B USD
Net Margin
13%
Country US
Market Cap 115.9B USD
Net Margin
-5%
Country US
Market Cap 112.4B USD
Net Margin
0%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 133.6B AUD
Net Margin
18%
Country US
Market Cap 82.6B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 34.5B EUR
Net Margin
-14%
No Stocks Found

GI Innovation Inc
Glance View

Market Cap
443.3B KRW
Industry
Biotechnology

GI Innovation, Inc. engages in the development of biopharmaceutical products. The company is headquartered in Seoul, Seoul and currently employs 88 full-time employees. The company went IPO on 2023-03-30. The firm is engaged in the business of generating revenue through license fees by technology transfer of new drug candidates in pre-clinical and early clinical stages. The core new drug pipeline includes products such as GI-101 immuno-oncology and GI-301 allergy treatment.

Intrinsic Value
9 325.56 KRW
Overvaluation 7%
Intrinsic Value
Price
G

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-983.3%
=
Net Income
-46.8B
/
Revenue
4.8B
What is the Net Margin of GI Innovation Inc?

Based on GI Innovation Inc's most recent financial statements, the company has Net Margin of -983.3%.